Indicated for: prevention and treatment of thromboembolism
Substance: apixaban (anticoagulant)
ATC: B01AF02 (Blood and blood forming organs | Antithrombotic agents | Direct factor xa inhibitors)
Apixaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thromboembolic disorders. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.